Serrapeptase Pregnancy Fix Jun 2026
Based on the precautionary principle and the absence of safety data:
A literature search was performed using PubMed, Scopus, and ToxNet (1960–2026) for terms: “serrapeptase,” “serratiopeptidase,” “pregnancy,” “placental transfer,” “teratogenicity,” and “fetal development.” Animal toxicology reports and FDA pregnancy categorization were extrapolated.
Serrapeptase is a proteolytic enzyme originally isolated from silkworms. While it is often marketed as a "miracle enzyme" for reducing inflammation and breaking down non-living tissue, its use in a prenatal context presents several significant concerns: serrapeptase pregnancy
A systematic search was conducted in April 2026 using:
Currently, there is to establish the safety of serrapeptase for pregnant women or developing fetuses. Based on the precautionary principle and the absence
Taking serrapeptase during pregnancy is due to a lack of reliable scientific research and clinical data on its safety for the mother and developing fetus. Why Avoid Serrapeptase During Pregnancy?
While serrapeptase is generally considered safe for most adults, its safety during pregnancy is uncertain. Due to the potential risks and concerns associated with its use, it's recommended that pregnant women avoid taking serrapeptase or consult with their healthcare provider before using it. Instead, consider alternative treatments that are considered safer and more effective for managing symptoms during pregnancy. Always consult with your healthcare provider before taking any supplements or medications during pregnancy. Taking serrapeptase during pregnancy is due to a
Grey literature (supplement labels, manufacturer safety data sheets) was also reviewed.
Bromelain (from pineapple) is also contraindicated in pregnancy due to uterine bleeding risk. Serrapeptase has (20× greater than bromelain in vitro), suggesting equal or greater hazard.
Serrapeptase lacks human pregnancy safety data and exhibits plausible teratogenic and hemorrhagic risks based on its mechanism (ECM degradation, fibrinolysis) and limited animal studies. Until high-quality prospective studies are conducted—unlikely due to ethical constraints—serrapeptase must be .
